Literature DB >> 1842905

Changes in alpha 1-acid glycoprotein serum concentrations and glycoforms in the developing human fetus.

N Seta1, B Tissot, F Forestier, J Feger, F Daffos, G Durand.   

Abstract

alpha 1-Acid glycoprotein concentrations and reactivity to concanavalin A were measured in maternal and fetal serum and amniotic fluid obtained from 24 women undergoing diagnostic cordocentesis at 20 to 33 wk gestation and in 30 additional fetal sera (19 to 34 weeks gestation). Maternal alpha 1-acid glycoprotein serum levels were five to ten times higher than fetal and amniotic levels. Fetal alpha 1-acid glycoprotein levels were found to increase with advancing gestational age. Using crossed immunoaffino electrophoresis with concanavalin A, alpha 1-acid glycoprotein patterns were identical in maternal serum and amniotic fluid but totally different in fetal serum. The fetal concanavalin A pattern changed progressively during fetal life towards that of the newborn. These data confirm earlier assumptions of fetal synthesis of alpha 1-acid glycoprotein and provide normal reference values for alpha 1-acid glycoprotein in fetal serum. In addition, the specific fetal concanavalin A pattern indicates that the alpha 1-acid glycoprotein glycosylation process during fetal life differs from that in post-natal life.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1842905     DOI: 10.1016/0009-8981(91)90288-n

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  7 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 2.  Measurement and analysis of unbound drug concentrations.

Authors:  J D Wright; F D Boudinot; M R Ujhelyi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

Review 3.  Carbohydrate composition and immunomodulatory activity of different glycoforms of alpha1-acid glycoprotein.

Authors:  S D Shiyan; N V Bovin
Journal:  Glycoconj J       Date:  1997-08       Impact factor: 2.916

4.  A Preterm Physiologically Based Pharmacokinetic Model. Part I: Physiological Parameters and Model Building.

Authors:  Khaled Abduljalil; Xian Pan; Amita Pansari; Masoud Jamei; Trevor N Johnson
Journal:  Clin Pharmacokinet       Date:  2020-04       Impact factor: 6.447

5.  Glycosylation of alpha1-acid glycoprotein in inflammatory disease: analysis by high-pH anion-exchange chromatography and concanavalin A crossed affinity immunoelectrophoresis.

Authors:  I Rydén; G Skude; A Lundblad; P Påhlsson
Journal:  Glycoconj J       Date:  1997-06       Impact factor: 2.916

6.  Inflammation throughout pregnancy and fetal growth restriction in rural Nepal.

Authors:  Michael W Sauder; Sun Eun Lee; Kerry J Schulze; Parul Christian; Lee S F Wu; Subarna K Khatry; Steven C LeClerq; Ramesh K Adhikari; John D Groopman; Keith P West
Journal:  Epidemiol Infect       Date:  2019-08-30       Impact factor: 2.451

Review 7.  Pharmacokinetic and Pharmacodynamic Considerations for Drugs Binding to Alpha-1-Acid Glycoprotein.

Authors:  Sherri A Smith; Nigel J Waters
Journal:  Pharm Res       Date:  2018-12-28       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.